Furthermore, targeting euchromatic histone-lysine N-methyltransferase 2 (EHMT2) can reverse EGFR-TKI resistance in NSCLC by epigenetically regulating the PTEN/AKT signaling pathway674 (Fig. 7). The gene discussed is AKT1; the disease is non-small cell lung carcinoma.